{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:24:21Z","timestamp":1792110261140,"version":"4.4.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To investigate the efficacy and risk factors of intravitreal antivascular endothelial growth factor injection (anti-VEGF therapy) for retinopathy of prematurity (ROP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We retrospectively reviewed 80 consecutive eyes of 43 patients with Type 1 ROP or worse who received anti-VEGF therapy during January 2012\u2013February 2018. Patients were divided into those who were injected with 0.25 mg of bevacizumab (IVB group, 37 eyes) and 0.25 mg of ranibizumab (IVR group, 43 eyes). Serum VEGF concentrations of 18 patients were measured before and after IVR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Antivascular endothelial growth factor injection therapy reduced ROP activity in all eyes; however, 14 eyes (17.5%) exhibited reactivation. The reactivation rates of the IVB and IVR groups were 13.5% and 20.9%, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.556). Multivariate logistic regression analysis showed that postmenstrual age \u226435 weeks at anti-VEGF therapy (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.014) and aggressive posterior ROP (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.044) was significantly associated with reactivation. Serum VEGF was significantly suppressed at Days 1 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and 7 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.012) after IVR and returned to the preinjection level by Day 14 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.210).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Both IVR and IVB seemed effective in reducing ROP activity. Reactivation after anti-VEGF therapy may be associated with younger postmenstrual age at anti-VEGF therapy and aggressive posterior ROP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000003196","type":"journal-article","created":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T15:57:47Z","timestamp":1620575867000},"page":"2261-2268","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":46,"title":["FACTORS ASSOCIATED WITH REACTIVATION AFTER INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB THERAPY IN INFANTS WITH RETINOPATHY OF PREMATURITY"],"prefix":"10.1097","volume":"41","author":[{"given":"Chiharu","family":"Iwahashi","sequence":"first","affiliation":[{"name":"Ophthalmology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Utamura","sequence":"additional","affiliation":[{"name":"Ophthalmology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Kuniyoshi","sequence":"additional","affiliation":[{"name":"Ophthalmology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sugioka","sequence":"additional","affiliation":[{"name":"Ophthalmology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Konishi","sequence":"additional","affiliation":[{"name":"Pediatrics, Kindai University Faculty of Medicine, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihisa","family":"Wada","sequence":"additional","affiliation":[{"name":"Pediatrics, Kindai University Faculty of Medicine, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8364-0948","authenticated-orcid":false,"given":"Shunji","family":"Kusaka","sequence":"additional","affiliation":[{"name":"Ophthalmology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010","volume":"74","author":"Blencowe","year":"2013","journal-title":"Pediatr Res"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.survophthal.2016.12.004","article-title":"Advances in understanding and management of retinopathy of prematurity","volume":"62","author":"Hartnett","year":"2017","journal-title":"Surv Ophthalmol"},{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"340","DOI":"10.5935\/0004-2749.20150090","article-title":"Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity","volume":"78","author":"Erol","year":"2015","journal-title":"Arq Bras Oftalmol"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"27082","DOI":"10.1038\/srep27082","article-title":"Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy","volume":"6","author":"Chan","year":"2016","journal-title":"Sci Rep"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/02713683.2016.1196709","article-title":"Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey","volume":"42","author":"Gunay","year":"2017","journal-title":"Curr Eye Res"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","article-title":"Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy","volume":"40","author":"Ling","year":"2020","journal-title":"Retina"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The international classification of retinopathy of prematurity revisited","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ophtha.2016.10.032","article-title":"Efficacy of primary intravitreal ranibizumab for retinopathy of prematurity in China","volume":"124","author":"Feng","year":"2017","journal-title":"Ophthalmology"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy","volume":"123","author":"Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","article-title":"Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan","volume":"118","author":"Wu","year":"2011","journal-title":"Ophthalmology"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","article-title":"An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan","volume":"155","author":"Wu","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis","volume":"122","author":"Hwang","year":"2015","journal-title":"Ophthalmology"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1167\/iovs.16-20680","article-title":"Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: timing and risk factors","volume":"58","author":"Lyu","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R19-20250607","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"Wong","year":"2015","journal-title":"Retina"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab","volume":"35","author":"Chen","year":"2015","journal-title":"Retina"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3109\/02713683.2015.1084643","article-title":"Effects of intravitreal ranibizumab in the treatment of retinopathy of prematurity in Chinese infants","volume":"41","author":"Yi","year":"2016","journal-title":"Curr Eye Res"},{"key":"R22-20250607","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","article-title":"Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity","volume":"37","author":"Zhang","year":"2017","journal-title":"Retina"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","article-title":"A dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments","volume":"125","author":"Wallace","year":"2018","journal-title":"Ophthalmology"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"5078565","DOI":"10.1155\/2017\/5078565","article-title":"Recurrence of retinopathy of prematurity in zone II stage 3+ after ranibizumab treatment: a retrospective study","volume":"2017","author":"Hu","year":"2017","journal-title":"J Ophthalmol"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1097\/IAE.0000000000001685","article-title":"Progressive retinal detachment in infants with retinopathy of prematurity treated with intravitreal bevacizumab or ranibizumab","volume":"38","author":"Yonekawa","year":"2018","journal-title":"Retina"},{"key":"R26-20250607","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000223949","article-title":"Anti-angiogenic therapy in the management of retinopathy of prematurity","volume":"44","author":"Drenser","year":"2009","journal-title":"Dev Ophthalmol"},{"key":"R27-20250607","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jcjo.2015.11.001","article-title":"Alterations in intraocular cytokine levels following intravitreal ranibizumab","volume":"51","author":"Forooghian","year":"2016","journal-title":"Can J Ophthalmol"},{"key":"R28-20250607","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/01.iae.0000244257.60524.89","article-title":"Lensectomy and vitrectomy with and without intravitreal triamcinolone acetonide for vascularly active stage 5 retinal detachments in retinopathy of prematurity","volume":"26","author":"Lakhanpal","year":"2006","journal-title":"Retina"},{"key":"R29-20250607","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":"Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study","volume":"92","author":"Kusaka","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R30-20250607","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1111\/aos.12055","article-title":"Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection","volume":"91","author":"Xu","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"R31-20250607","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","article-title":"Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity","volume":"91","author":"Hoerster","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"R32-20250607","first-page":"2985161","article-title":"Serum vascular endothelial growth factor levels before and after intravitreous ranibizumab injection for retinopathy of prematurity","volume":"37","author":"Chen","year":"2019","journal-title":"J Ophthalmol"},{"key":"R33-20250607","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00417-015-2996-0","article-title":"Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab","volume":"254","author":"Zhou","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T14:04:23Z","timestamp":1749305063000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,7]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003196","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,7]]}}}